PropertyValue
?:abstract
  • INTRODUCTION: Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic Conflicting evidence about its usefulness has begun to accrue METHODS: In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials RESULTS: Five studies investigating 2291 subjects were included The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4 57, 95% confidence interval 2 14-9 45 CONCLUSION: Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit
is ?:annotates of
?:creator
?:journal
  • Immun_Inflamm_Dis
  • Immunity,_Inflammation_and_Disease
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials
?:type
?:who_covidence_id
  • #1064360
  • #946981
?:year
  • 2020
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/9998s7e6>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/9998s7e6>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all